Selvita and Ardigen Will Receive Funding for the Development of an AI-based High-content Screening Platform

Selvita S.A. (WSE: SLV) - one of the largest preclinical contract research organizations in Europe, has signed a grant agreement with the National Centre for Research and Development for the development of a cell-based phenotypic platform based on high content imaging system integrated with artificial intelligence data analysis for multiple therapeutic areas, including neuroinflammatory and fibrosis drug discovery (HiScAI - High Content Screening Artificial Intelligence).